ORYZON GENOMICS S.A. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.048 EUR | +0.89% |
|
+3.51% | +7.79% |
| 05-06 | Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-22 | Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat | CI |
- Stock Market
- Equities
- ORY Stock
- Charts Oryzon Genomics S.A.
- Static Chart